Spero Therapeutics (SPRO) Common Equity (2016 - 2026)

Spero Therapeutics has reported Common Equity for 11 years, with the latest figure at $52.9 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 56.54% year-over-year to $52.9 million; the trailing twelve-month figure through Mar 2026 stood at $52.9 million (up 56.54% YoY), and the FY2025 full-year result was $59.0 million, up 27.96% from the prior year.
• Common Equity for Q1 2026 stood at $52.9 million, down from $59.0 million in the prior quarter.
• The five-year high for Common Equity was $106.9 million in Q4 2023, with the low at $26.5 million in Q3 2025.
• Historically, Common Equity has averaged $57.7 million across 5 years, with a median of $54.8 million in 2023.
• Annual changes were most pronounced in 2022 — Common Equity slumped 70.97% — and 2023, when it soared 65.33%.
• Spero Therapeutics' Common Equity stood at $75.9 million in 2022, then soared by 40.77% to $106.9 million in 2023, then tumbled by 56.85% to $46.1 million in 2024, then rose by 27.96% to $59.0 million in 2025, then dropped by 10.31% to $52.9 million in 2026.
• The last three Common Equity figures came in at $52.9 million (Q1 2026), $59.0 million (Q4 2025), and $26.5 million (Q3 2025), per Business Quant data.